Kezar Life Sciences, Inc. — Net Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/c18796cf-f2e8-4534-9ccd-64b761c2a92c/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-56.0M | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-021737 |
| FY 2024 | $-83.7M | 2024-01-01 – 2024-12-31 | evidence 0001645666-25-000010 |
| FY 2023 | $-101.9M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-031494 |
| FY 2022 | $-68.2M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-007871 |
| FY 2021 | $-54.6M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-004085 |
| FY 2020 | $-41.7M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-012525 |
| FY 2019 | $-35.1M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-010498 |
| FY 2018 | $-23.2M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-009369 |
| FY 2017 | $-8.5M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-009369 |
| FY 2016 | $-9.0M | 2016-01-01 – 2016-12-31 | evidence 0001564590-19-009369 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Kezar Life Sciences, Inc. — all facts · Revenue · Operating Income